Related Experiment Video

Updated: Jan 29, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer

Kumar Nikhil1, Lei Chang1, Keith Viccaro1

  • 1Department of Chemistry and Purdue University Center for Cancer Research, 560 Oval Drive, West Lafayette, IN, 47907, USA.

Cancer Letters
|February 5, 2019
PubMed

Insights

The study identifies LIMK2 kinase as a key target in castration-resistant prostate cancer (CRPC). Inhibiting LIMK2 reverses CRPC progression, offering a promising therapeutic strategy with minimal toxicity for patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer progression to castration-resistant prostate cancer (CRPC) remains a significant clinical challenge.
  • Androgen deprivation therapy (ADT) is a standard treatment, but resistance develops, leading to CRPC.
  • Identifying novel therapeutic targets is crucial for improving CRPC patient outcomes.

Purpose of the Study:

  • To identify and validate LIMK2 kinase as a disease-specific target in CRPC pathogenesis.
  • To elucidate the molecular mechanism underlying LIMK2-mediated CRPC progression.
  • To evaluate the therapeutic potential of targeting LIMK2 in CRPC.

Main Methods:

  • Analysis of LIMK2 expression in human prostate cancer tissues across different stages.
  • Investigating the effect of surgical castration and hypoxia on LIMK2 expression in mouse models.
  • Utilizing inducible knockdown of LIMK2 in mouse models to assess its role in CRPC tumorigenesis.
  • Identifying and characterizing TWIST1 as a direct substrate of LIMK2, including phosphorylation and ubiquitylation studies.
  • Evaluating the impact of phosphorylation-dead TWIST1 on epithelial-mesenchymal transition (EMT) and tumor formation in vivo.

Main Results:

  • LIMK2 kinase is upregulated in CRPC tissues and in response to androgen deprivation and hypoxia.
  • Inducible knockdown of LIMK2 completely reverses CRPC tumorigenesis in castrated mice.
  • TWIST1 is identified as a direct substrate of LIMK2, with LIMK2 stabilizing TWIST1 via phosphorylation.
  • TWIST1 reciprocally stabilizes LIMK2 by inhibiting its ubiquitylation, forming a crucial signaling axis.
  • Phosphorylation-dead TWIST1 prevents EMT and tumor formation, confirming the critical role of the LIMK2-TWIST1 interaction.

Conclusions:

  • LIMK2 is a critical driver of CRPC and a promising therapeutic target.
  • The LIMK2-TWIST1 signaling axis is central to CRPC initiation, progression, and poor prognosis.
  • Targeting LIMK2 offers a potential strategy for CRPC treatment with minimal predicted toxicity, potentially improving patient survival.
Keywords:
Castration resistant prostate cancerLIMK2Prostate cancerTWIST1

More Related Videos

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.6K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.9K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.5K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
6.0K
Therapeutic Index01:13

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K
Equivalent Resistance01:16

Equivalent Resistance

In circuit analysis, situations often arise where resistors are neither in series nor parallel configurations. To tackle such scenarios, three-terminal equivalent networks like the wye (Y) (Figure 1 (a)) or tee (T) and delta (Δ) (Figure 1 (b)) or pi (π) networks come into play. These networks offer versatile solutions and are frequently encountered in various applications, including three-phase electrical systems, electrical filters, and matching networks.
977